Skinbiotherapeutics (SBTX)

Company name:Skinbiotherapeutics Plc
Company Description:SkinBioTherapeutics is a life science company focused on skin health.
EPIC:SBTXTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BF33H870
Market Segment:ASQ1Share Type:DE
WWW Address: 1P
 Price Price Change [%] Bid Offer Open High Low Volume
 64.00 -1.0 [-1.54] 63.00 65.00 65.50 65.50 64.00 83,363
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 99.77 155.89 0.00 -1.17 - - - 87.00 - 7.58

Skinbiotherapeutics Key Figures

(at previous day's close)
Market Cap.99.77m
Shares In Issue155.89m
Prev. Close65.00
PE Ratio- 
Dividend Yield-%
EPS - basic-1.17p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-0.57p
Return On Equity (ROE)-60.83%
Operating Margin-%
PEG Factor- 
EPS Growth Rate-24.47%
Dividends PS Growth Rate-%
Net Debt-1.85m
Gross Gearing11.00%
Quick Assets2.35m
Net Working Capital2.04m
Intangibles / Fixed Assets99.60%
Turnover PS-p
Pre-Tax Profit PS-1.04p
Retained Profit PS-0.10p
Cash PS1.38p
Net Cash PS1.19p
Net Tangible Asset Value PS *1.31p
Net Asset Value PS1.58p
Spread2.00 (3.08%) 

Skinbiotherapeutics Balance Sheet


Share Price Performance

Sample Period HighLow
1 week66.5062.00
4 weeks66.5053.50
12 weeks87.0053.50
1 year87.007.58

Share Price Chart (5 years)

Skinbiotherapeutics Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week63.001.001.5962.000.3664.37
4 weeks60.703.305.4453.500.5560.67
12 weeks64.00--53.500.8265.05
26 weeks35.0029.0082.8634.250.9556.36
1 year24.4039.60162.307.580.9241.99
3 years26.2537.75143.815.750.5830.11
5 years13.2550.75383.025.750.5226.32

Skinbiotherapeutics Key Management Ratios

Skinbiotherapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 29.77 
Tobin's Q Ratio (excl. intangibles)33.62 
Dividend Yield-%
Market-to-Book Ratio40.46 
Price-to-Pre-Tax Profit PS-61.58 
Price-to-Retained Profit PS-664.75 
Price-to-Cash Flow PS-111.83 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS48.78 
Price-to-Cash PS46.21 
Net Working Capital PS1.31 
Price Pct to Working Capital PS48.82%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Skinbiotherapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing-66.92%
Net Gearing (excl. Intangibles)-78.90%
Gross Gearing11.00%
Gross Gearing (excl. Intangibles)12.97%
Gearing Under 1 Year11.00%
Gearing Under 1 Year (excl. Intgbl)12.97%
(Liquidity Ratios)
Net Working Capital to Total Assets73.76%
Current Ratio7.70 
Quick Ratio (Acid Test)7.70 
Liquidity Ratio7.08 
Cash & Equiv/Current Assets91.94%
(Solvency Ratios)
Enterprise Value97.61m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.00 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.19 
Total Debt0.30m
Total Debt/Net Current Assets0.15%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs2 
Beta (60-Mnth)Beta (36-Mnth)

Skinbiotherapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-65.70%
Return On Assets (ROA)-44.76%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-60.83%
Return On Investment (ROI)-47.80%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debt Collection Period-Days

Skinbiotherapeutics Dividends

Sorry No Data Available

Skinbiotherapeutics Fundamentals

 30 Jun 2017 (GBP)30 Jun 2018 (GBP)30 Jun 2019 (GBP)30 Jun 2020 (GBP)
pre tax profit-0.69--0.94--1.36--1.62-m
attributable profit-0.65--0.84--1.15--1.50-m
retained profit-0.65--0.84--1.15--0.15-m
eps - basic (p)-1.11 -0.71 -0.94 -1.17 
eps - diluted (p)-1.11 -0.71 -0.94 -1.17 
dividends per share- - - - 

Skinbiotherapeutics Balance Sheet

 30 Jun 2017 (GBP)30 Jun 2018 (GBP)30 Jun 2019 (GBP)30 Jun 2020 (GBP)
 30 Jun 2017 (GBP)30 Jun 2018 (GBP)30 Jun 2019 (GBP)30 Jun 2020 (GBP)
fixed assets fixed assets--%--%0.010.17%0.000.06%m
intangibles intangibles0.224.97%0.297.88%0.358.82%0.4215.18%m
fixed investments fixed investments--%--%--%0.000.00%m
current assets - other current assets - other0.040.99%--%--%--%m
stocks stocks--%--%--%--%m
debtors debtors0.153.49%0.184.92%0.4511.52%0.196.84%m
cash & securities cash & securities3.9290.55%3.1887.20%3.1279.48%2.1677.93%m
creditors - short creditors - short0.122.74%0.215.73%0.123.09%0.3011.00%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves4.2197.26%3.4494.27%3.8196.91%2.4789.00%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Skinbiotherapeutics Cash Flow Statement

30 Jun 2017 (GBP)30 Jun 2018 (GBP)30 Jun 2019 (GBP)30 Jun 2020 (GBP)
Operating CF-0.61-0.67-1.43-0.89m
Pre-Financing CF-0.69-0.74-1.50-0.97m
Retained CF3.67-0.74-0.06-0.97m

Skinbiotherapeutics Brokers

Broker infomation is not available for this class of stock.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210805 12:48:21